Journal of the American Society of Hypertension
Volume 2, Issue 4, Supplement , Pages S23-S29 , July 2008

Does it matter how blood pressure is lowered in patients with metabolic risk factors?

Based on material presented at a Boehringer Ingelheim- Sponsored Meeting held in Madrid, Spain, May 4–5, 2007.

  • Arya M. Sharma, MD, FRCP(C)

      Affiliations

    • Corresponding Author InformationCorresponding author: Arya M. Sharma, MD, FRCP(C), Chair for Obesity Research and Management, University of Alberta, Royal Alexandra Hospital, 10240 Kingsway Avenue, Edmonton AB T5H 3V9, Canada. Tel: 780-735-5859; fax: 780-735-5861.

References 

  1. Sharma AM. Obesity and cardiovascular risk. Growth Horm IGF Res. 2003;13:S10–S17
  2. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA. 1999;282:1523–1529
  3. Stamler J, Stamler R, Riedlinger WF, Algera G, Roberts RH. Hypertension screening of 1 million Americans (Community Hypertension Evaluation Clinic (EHEC) Program, 1973 through 1975). JAMA. 1976;235:2299–2306
  4. Kannel WB, Garrison RJ, Dannenberg AL. Secular blood pressure trends in normotensive persons: the Framingham Study. Am Heart J. 1993;125:1154–1158
  5. Anderson JW, Konz EC. Obesity and disease management: effects of weight loss on comorbid conditions. Obes Res. 2001;9:326S–334S
  6. Mertens IL, van Gaal LF. Overweight, obesity, and blood pressure: the effects of modest weight reduction. Obes Res. 2000;8:270–278
  7. World Health Organization. Report of a WHO Consultation on Obesity. In: Obesity: Preventing and Managing the Global Epidemic. Geneva, Switzerland: World Health Organization; 1998;p. 43–4456
  8. Alexander LM. Desirable therapeutic characteristics of an optimal antihypertensive agent. Drugs. 2006;66:1239–1252
  9. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART Study): case-control study. Lancet. 2004;364:937–952
  10. Douketis JD, Paradis G, Keller H, Martineau C. Canadian guidelines for body weight classification in adults: application in clinical practice to screen for overweight and obesity and to assess disease risk. CMAJ. 2005;172:995–998
  11. Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet. 2005;366:1640–1649
  12. Sharma AM. Adipose tissue: a mediator of cardiovascular risk. Int J Obes. 2002;26:S5–S7
  13. Lau DCW, Douketis JD, Morrison KM, Hramiak IM, Sharma AM, Ur E Obesity Canada Clinical Practice Guidelines Expert Panel. 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children. [summary] CMAJ. 2007;176:S1–S13
  14. Scholze J, Grimm E, Herrmann D, Unger T, Kintscher U. Optimal treatment of obesity-related hypertension (The Hypertension-Obesity-Sibutramine (HOS) Study). Circulation. 2007;115:1991–1998
  15. United Kingdom Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ. 1998;317:713–720
  16. Sharma AM, Pischon T, Hardt S, Kunz I, Luft SC. β-adrenergic receptor blockers and weight gain (A systematic analysis). Hypertension. 2001;37:250–254
  17. Kunz I, Schorr U, Klaus S, Sharma AM. Resting metabolic rate and substrate use in obesity hypertension. Hypertension. 2000;36:26–32
  18. Buemann B, Astrup A, Madsen J, Christensen NJ. A 24-hour energy expenditure study on reduced-obese and nonobese women: effect of beta-blockade. Am J Clin Nutr. 1992;56:662–670
  19. Van Baak MA, Bohm RO, Arends BG, van Hooff ME, Rahn KH. Long-term antihypertensive therapy with beta-blockers: submaximal exercise capacity and metabolic effects during exercise. Int J Sports Med. 1987;8:342–347
  20. Welle S, Schwartz RG, Statt M. Reduced metabolic rate during beta-adrenergic blockade in humans. Metabolism. 1991;40:619–622
  21. Astrup A, Simonsen L, Bulow J, Madsen J, Christensen NJ. Epinephrine mediates facultative carbohydrate-induced thermogenesis in human skeletal muscle. Am J Physiol. 1989;257:E340–E345
  22. Koch G, Franz IW, Lohmann FW. Effects of short-term and long-term treatment with cardio-selective and non-selective beta-receptor blockade on carbohydrate and lipid metabolism and on plasma catecholamines at rest and during exercise. Clin Sci. 1981;61:S433–S435
  23. Gress TW, Nieto FJ, Shahar E, Woffard MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med. 2000;342:905–912
  24. Barzilay JI, Davis BR, Cutler JA, Pressel SL, Whelton PK, Basile J, et al. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment (A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)). Arch Intern Med. 2006;166:2191–2201
  25. Scheen AJ. VALUE: analysis of results. [letter] Lancet. 2004;364:932–933
  26. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet. 2002;359:995–1003
  27. Engeli S, Böhnke J, Gorzelniak K, Janke J, Schling P, Bader M, et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension. 2005;45:356–362
  28. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev. 2000;21:697–738
  29. Sharma AM, Staels B. Review: peroxisome proliferator-activated receptor gamma and adipose tissue—understanding obesity-related changes in regulation of lipid and glucose metabolism. J Clin Endocrinol Metab. 2007;92:386–395
  30. Janke J, Engeli S, Gorzelniak K, Luft FC, Sharma AM. Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin-type 1 receptors. Diabetes. 2002;51:1699–1707
  31. Gorzelniak K, Engeli S, Janke J, Luft FC, Sharma AM. Hormonal regulation of the human adipose-tissue renin-angiotensin system: relationship to obesity and hypertension. J Hypertens. 2002;20:965–973
  32. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest. 2004;114:1752–1761
  33. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity. Hypertension. 2004;43:993–1002
  34. Shimabukuro M, Tanaka H, Shimabukuro T. Effects of telmisartan on fat distribution in individuals with the metabolic syndrome. J Hypertens. 2007;25:841–848
  35. Sharma AM, Davidson JA, Gavin JR, DeSousa NJ. Comparison of the antihypertensive efficacy of telmisartan/hydrochlorothiazide vs. valsartan/hydrochlorothiazide in high-risk overweight/obese patients with hypertension and type 2 diabetes. Hypertension. 2005;46:898–899

 Conflict of interest: none.

PII: S1933-1711(08)00043-0

doi: 10.1016/j.jash.2008.03.006

Journal of the American Society of Hypertension
Volume 2, Issue 4, Supplement , Pages S23-S29 , July 2008

Article Tools

* Image Usage & Resolution